423 related articles for article (PubMed ID: 38275910)
1. Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.
Al Hmada Y; Brodell RT; Kharouf N; Flanagan TW; Alamodi AA; Hassan SY; Shalaby H; Hassan SL; Haikel Y; Megahed M; Santourlidis S; Hassan M
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275910
[TBL] [Abstract][Full Text] [Related]
2. Cancer stem cell as therapeutic target for melanoma treatment.
Alamodi AA; Eshaq AM; Hassan SY; Al Hmada Y; El Jamal SM; Fothan AM; Arain OM; Hassan SL; Haikel Y; Megahed M; Hassan M
Histol Histopathol; 2016 Dec; 31(12):1291-301. PubMed ID: 27301538
[TBL] [Abstract][Full Text] [Related]
3. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
4. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
5. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
[TBL] [Abstract][Full Text] [Related]
6. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
7. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
8. Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.
Mordoh A; Triviño Pardo JC; Carri I; Barrio MM; Mordoh J; Aris M
BMC Med Genomics; 2023 Jan; 16(1):1. PubMed ID: 36604730
[TBL] [Abstract][Full Text] [Related]
9. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
10. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
[TBL] [Abstract][Full Text] [Related]
11. Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF
Torres-Collado AX; Knott J; Jazirehi AR
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29795041
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
Yeon M; Kim Y; Jung HS; Jeoung D
Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
[TBL] [Abstract][Full Text] [Related]
13. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI; Widmer DS; Narechania A; Eichhoff O; Freiberger SN; Wenzina J; Cheng PF; Mihic-Probst D; Desalle R; Dummer R; Levesque MP
Oncotarget; 2016 Nov; 7(47):77163-77174. PubMed ID: 27791198
[TBL] [Abstract][Full Text] [Related]
14. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
[TBL] [Abstract][Full Text] [Related]
15. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility.
Marzagalli M; Montagnani Marelli M; Casati L; Fontana F; Moretti RM; Limonta P
Front Endocrinol (Lausanne); 2016; 7():140. PubMed ID: 27833586
[TBL] [Abstract][Full Text] [Related]
17. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
[TBL] [Abstract][Full Text] [Related]
18. NRAS mutant melanoma: Towards better therapies.
Randic T; Kozar I; Margue C; Utikal J; Kreis S
Cancer Treat Rev; 2021 Sep; 99():102238. PubMed ID: 34098219
[TBL] [Abstract][Full Text] [Related]
19. Histologic and Phenotypic Factors and MC1R Status Associated with BRAF(V600E), BRAF(V600K), and NRAS Mutations in a Community-Based Sample of 414 Cutaneous Melanomas.
Hacker E; Olsen CM; Kvaskoff M; Pandeya N; Yeo A; Green AC; Williamson RM; Triscott J; Wood D; Mortimore R; Hayward NK; Whiteman DC
J Invest Dermatol; 2016 Apr; 136(4):829-837. PubMed ID: 26807515
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
Jandova J; Wondrak GT
J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
